| Year |
Citation |
Score |
| 2024 |
Beshiri ML, Capaldo BJ, Lake R, Ku AT, Burner D, Tice CM, Tran C, Kostas J, Alilin AN, Yin JJ, Agarwal S, Morris SA, Karzai FH, Lotan TL, Dahut WL, ... ... Kelly K, et al. Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate resistant prostate cancer. Stem Cells (Dayton, Ohio). PMID 38563224 DOI: 10.1093/stmcls/sxae025 |
0.358 |
|
| 2023 |
Agarwal S, Fang L, McGowen K, Yin J, Bowman J, Ku AT, Alilin AN, Corey E, Roudier MP, True LD, Dumpit RF, Coleman I, Lee JK, Nelson PS, Capaldo BJ, ... ... Kelly K, et al. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models. The Journal of Clinical Investigation. PMID 37725435 DOI: 10.1172/JCI162148 |
0.337 |
|
| 2023 |
Beshiri M, Agarwal S, Yin JJ, Kelly K. Prostate organoids: emerging experimental tools for translational research. The Journal of Clinical Investigation. 133. PMID 37183816 DOI: 10.1172/JCI169616 |
0.435 |
|
| 2022 |
Whitlock NC, White ME, Capaldo BJ, Ku AT, Agarwal S, Fang L, Wilkinson S, Trostel SY, Shi ZD, Basuli F, Wong K, Jagoda EM, Kelly K, Choyke PL, Sowalsky AG. Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A. Discover. Oncology. 13: 97. PMID 36181613 DOI: 10.1007/s12672-022-00565-3 |
0.406 |
|
| 2022 |
Fang L, Li D, Yin J, Pan H, Ye H, Bowman J, Capaldo B, Kelly K. TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence. Cancer Gene Therapy. PMID 35393570 DOI: 10.1038/s41417-022-00454-5 |
0.476 |
|
| 2021 |
Roy J, White ME, Basuli F, Opina ACL, Wong K, Riba M, Ton AT, Zhang X, Jansson KH, Edmondson E, Butcher D, Lin FI, Choyke PL, Kelly K, Jagoda EM. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [F]DCFPyL PET Imaging. Molecular Imaging and Biology. PMID 33891265 DOI: 10.1007/s11307-021-01605-0 |
0.335 |
|
| 2021 |
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, ... ... Kelly K, et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications. 12: 1979. PMID 33785741 DOI: 10.1038/s41467-021-22139-7 |
0.466 |
|
| 2020 |
Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics. PMID 32371590 DOI: 10.1158/1535-7163.Mct-19-0936 |
0.326 |
|
| 2020 |
Kelly K. Profiling prostate biology. Science (New York, N.Y.). 368: 467-468. PMID 32355016 DOI: 10.1126/science.abb7052 |
0.414 |
|
| 2019 |
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, ... ... Kelly K, et al. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Reports. 29: 2355-2370.e6. PMID 31747605 DOI: 10.1016/J.Celrep.2019.10.068 |
0.441 |
|
| 2019 |
Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31363002 DOI: 10.1158/1078-0432.Ccr-19-1423 |
0.462 |
|
| 2019 |
Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, Beshiri ML, Fang L, Lake RG, Agarwal S, Alilin AN, Xu W, Yin J, Kelly K. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. PMID 31312026 DOI: 10.1038/S41388-019-0873-8 |
0.336 |
|
| 2018 |
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. Journal For Immunotherapy of Cancer. 6: 141. PMID 30514390 DOI: 10.1186/S40425-018-0463-2 |
0.345 |
|
| 2018 |
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KA, Yin JJ, Alilin AN, Karzai FH, Dahut W, Corey E, Kelly K. A PDX/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29748182 DOI: 10.1158/1078-0432.Ccr-18-0409 |
0.42 |
|
| 2017 |
Pan H, Jansson KH, Beshiri ML, Yin J, Fang L, Agarwal S, Nguyen H, Corey E, Zhang Y, Liu J, Fan H, Lin H, Kelly K. Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer. Oncotarget. 8: 77181-77194. PMID 29100379 DOI: 10.18632/Oncotarget.20424 |
0.331 |
|
| 2017 |
Pan H, Lu LY, Wang XQ, Li BX, Kelly K, Lin HS. Gambogic acid induces cell apoptosis and inhibits MAPK pathway in PTEN(-/-)/p53(-/-) prostate cancer cells in vitro and ex vivo. Chinese Journal of Integrative Medicine. PMID 28578487 DOI: 10.1007/s11655-017-2410-3 |
0.387 |
|
| 2015 |
Agarwal S, Hynes PG, Tillman HS, Lake R, Abou-Kheir WG, Fang L, Casey OM, Ameri AH, Martin PL, Yin JJ, Iaquinta PJ, Karthaus WR, Clevers HC, Sawyers CL, Kelly K. Identification of Different Classes of Luminal Progenitor Cells within Prostate Tumors. Cell Reports. 13: 2147-58. PMID 26628377 DOI: 10.1016/J.Celrep.2015.10.077 |
0.347 |
|
| 2014 |
Siu MK, Abou-Kheir W, Yin JJ, Chang YS, Barrett B, Suau F, Casey O, Chen WY, Fang L, Hynes P, Hsieh YY, Liu YN, Huang J, Kelly K. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget. 5: 3770-84. PMID 25004126 DOI: 10.18632/Oncotarget.1994 |
0.303 |
|
| 2014 |
Yin J, Liu YN, Tillman H, Barrett B, Hewitt S, Ylaya K, Fang L, Lake R, Corey E, Morrissey C, Vessella R, Kelly K. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Research. 74: 4306-17. PMID 24970477 DOI: 10.1158/0008-5472.CAN-13-3233 |
0.441 |
|
| 2012 |
Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R, Zhang L, Kelly K. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. Plos One. 7: e41668. PMID 22860005 DOI: 10.1371/journal.pone.0041668 |
0.361 |
|
| 2012 |
Hynes PG, Kelly K. Prostate cancer stem cells: The case for model systems. Journal of Carcinogenesis. 11: 6. PMID 22529742 DOI: 10.4103/1477-3163.93701 |
0.447 |
|
| 2012 |
Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O, Hu D, Wan Y, Seng V, Sheppard-Tillman H, Martin P, Kelly K. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Molecular and Cellular Biology. 32: 941-53. PMID 22203039 DOI: 10.1128/Mcb.06306-11 |
0.487 |
|
| 2011 |
Abou-Kheir W, Hynes PG, Martin P, Yin JJ, Liu YN, Seng V, Lake R, Spurrier J, Kelly K. Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity. Plos One. 6: e26112. PMID 22022528 DOI: 10.1371/Journal.Pone.0026112 |
0.468 |
|
| 2011 |
Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, Kelly K. LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Research. 71: 7301-11. PMID 21978933 DOI: 10.1158/0008-5472.Can-11-2381 |
0.309 |
|
| 2011 |
Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V, Camacho D, Simpson RM, Kelly K. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. The American Journal of Pathology. 179: 422-35. PMID 21703421 DOI: 10.1016/J.Ajpath.2011.03.035 |
0.403 |
|
| 2010 |
Abou-Kheir WG, Hynes PG, Martin PL, Pierce R, Kelly K. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells (Dayton, Ohio). 28: 2129-40. PMID 20936707 DOI: 10.1002/stem.538 |
0.508 |
|
| 2008 |
Kelly K, Yin JJ. Prostate cancer and metastasis initiating stem cells. Cell Research. 18: 528-37. PMID 18414448 DOI: 10.1038/cr.2008.50 |
0.466 |
|
| 2007 |
Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, Kelly K. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Molecular and Cellular Biology. 27: 7538-50. PMID 17709381 DOI: 10.1128/MCB.00955-07 |
0.353 |
|
| Show low-probability matches. |